Phospholipase C delta-3 (PLCD3)

Phospholipase C delta-3 (PLCD3) is an enzyme that catalyzes the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) to generate the second messengers diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). These signaling molecules play central roles in diverse cellular functions, including the activation of protein kinase C (PKC), mobilizing intracellular calcium, and integrating responses to extracellular stimuli through signal transduction pathways. PLCD3 is essential in processes such as trophoblast and placental development, regulation of heart and neuronal functions, and may be involved in cancer proliferation and migration, as well as cardiovascular and lipid metabolism disorders. The protein contains key domains characteristic of the PLC family, including an N-terminal pleckstrin homology (PH) domain, EF-hand motifs, a catalytic (X/Y region) domain, and a C2 domain that influences membrane binding. While implicated in human disease, PLCD3 is not currently the direct target of any approved drugs.

Other names

1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase delta-3PLC-delta-3Phosphoinositide phospholipase C-delta-3KIAA1964Phospholipase C delta 3

For phospholipase C enzymes generally, inhibition or modulation would reduce PIP2 hydrolysis, dampen DAG/IP3 signaling, and downstream PKC activation or Ca2+ signaling. For PLCD3 specifically, no clinically validated direct modulators or inhibitors are described; drugs may target upstream signaling cascades or broader PLC activity.